

# Audio Conference

---

**Half-year activities and financials presentation**

*Closing Sept. 30 2018*

Audio Conference

# ***Agenda***

- Management presentation
- Answers to shareholders' questions

*You can send your questions by using the chat on the right of your screen*



# Audio Conference

---

- **Christophe Douat**  
*CEO*
- **Nicolas Heuzé**  
*Director Corporate  
Development  
& Corporate Finance*
- **Jaime Arango**  
*CFO*
- **Christophe Roberge**  
*Chief Technology Officer*



***Christophe Douat***



## ***Product development steps***

- *Formulation Research*
- *Non-clinical development*
- *Clinical development  
(phases I, II and III)*



## ***First Phase III in the United States***

- *mdc-IRM*  
Treatment for schizophrenia  
in partnership with Teva



## ***Products in development***

- *mdc-CWM*  
Launch of the first clinical trial (Phase II) in the United States



## ***Products in development***

- *mdc-TJK*  
Initiation of non-clinical development activities in partnership with Teva





## ***7 products in formulation research***



***Christophe Douat***



***Jaime Arango***



## ***Half-year financials***

- *Strong financial visibility*
  - €11,4 M in available funds
  - €4,6 M in non-risky financial assets



## ***Half-year financials***

- *Financial operations*
  - *BEI loan (€20 M)*
  - *Convertible bonds (€3,2 M)*



## ***Post-closing event***

- *IPO*
  - *€31.4 M of gross proceeds  
(before issue premiums)*



## ***Operating expenses***

- €8,4 M  
(+24% vs half-year 2017)



## ***Financial expenses***

- €3,3 M  
*including €2,3 M of exceptional  
financial expenses generated  
by IPO*





***Jaime Arango***

# Q&A

*You can send your questions by using the chat on the right of your screen*



*THANK YOU*

MedinCell  
3, rue des frères Lumière  
34830 Jacou • France

[www.medincell.com](http://www.medincell.com)